JAK inhibitors — tofacitinib and upadacitinib — have received NMPA approval for ankylosing spondylitis, representing the first small-molecule oral disease-modifying options beyond NSAIDs for Chinese AS patients who cannot access or tolerate biologic therapy, with the China Sacroiliitis Treatment Market reflecting the emerging JAK inhibitor market position in China's...
0 Commentarios
0 Acciones
364 Views
0 Vista previa
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek